EVER Pharma Gained EU-Approval of Testosterone Enantate

EVER Pharma, a fully integrated specialty pharmaceuticals company, is pleased toannounce the approval of Testosterone Enantate in the European Union for thetreatment of male hypogonadism. This condition, characterized by insufficienttestosterone production, affecting up to 10% of men globally and 40% of men aged 45.

Male hypogonadism can significantly impact a person’s quality of life, manifesting through symptoms such as reduced muscle mass, fatigue, and low libido. Testosterone Enantate is a long-acting injectable testosterone that has been proven to effectively alleviate these symptoms, improving patients’ overall well-being2.

“With male hypogonadism profoundly affecting quality of life, effective treatments are essential. We are happy to provide this therapy and enhance access to patients suffering from this condition,” said Georges Kahwati, General Manager of EVER Pharma.

The approval of Testosterone Enanthate underscores EVER Pharma’s expertise in developing and manufacturing hormone therapies. It also reaffirms the company’s dedication to providing essential pharmaceuticals to patients. A global rollout is planned.